UBS Says Pfizer Has 'Underappreciated' Oncology Portfolio After ASCO

By: via Benzinga
In a report published Wednesday, UBS analyst Marc Goodman maintained a Buy rating on Pfizer Inc (NYSE: PFE), with a price target of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.